Sickle Cell Kidney (SCeK) Biorepository

Status: Recruiting
Location: See all (2) locations...
Study Type: Observational
SUMMARY

Kidney disease is a major cause of illness and death in people with sickle cell disease and sickle cell trait. Despite these concerning facts, we do not (1) have an in-depth understanding of how kidney disease starts in sickle cell disease and sickle cell trait, (2) have detailed insights into why kidney disease is worse in people with sickle cell disease and sickle cell trait, (3) have management options that are tailored to treating or preventing kidney disease in people with sickle cell disease or sickle cell trait. The SCeK Biorepository is a specialized, secure repository designed for the collection of blood and urine samples from people with sickle cell disease and sickle cell trait. These samples are connected to detailed medical records, with the sole purpose of allowing researchers to better understand how kidney disease starts and progresses in people with the sickle cell gene. By studying these stored samples (using new tests) together with health information, researchers can find better early warning signs of kidney injury and develop better ways to protect kidney health in people with sickle cell disease and sickle cell trait.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: t
View:

• Age over 18 years,

• Estimated glomerular filtration rate greater than or equal to 15 mL/min,

• Presence of any hemoglobinopathy (will need to be confirmed by hemoglobin electrophoresis or genetic testing),

• Controls (absence of hemoglobinopathy) will be subject to review and only selected if demographics are identical to a currently enrolled participant with a hemoglobinopathy.

Locations
United States
Texas
Parkland Memorial Hospital
RECRUITING
Dallas
University of Texas Southwestern Medical Center
RECRUITING
Dallas
Contact Information
Primary
Kabir O Olaniran, MD, MPH, FASN
SCeK@UTSouthwestern.edu
214-645-8267
Time Frame
Start Date: 2024-08-22
Estimated Completion Date: 2049-12
Participants
Target number of participants: 800
Sponsors
Leads: University of Texas Southwestern Medical Center

This content was sourced from clinicaltrials.gov